Here are four things to know:
1. Brean Capital currently has a “buy” rating on the stock.
2. NuVasive has a one-year low of $31.35 and a one-year high of $51.23.
3. The stock has a 50-day moving average of $47.23 and a 200-day moving average of $41.65.
4. NuVasive’s market cap is $2.139 billion.
More articles on devices:
Spine device company stock report: 5 key companies — Feb. 26
Invibio Spine’s PEEK-OPTIMA HA Enhanced shows promise
JMEA Corporation wins grant from Montgomery County’ economic development department
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
